Chondrogenesis and Osteoarthritis
VIP advances chondrogenesis in mesenchymal stem cells and reduces inflammatory and ECM-degrading mediators in osteoarthritis chondrocytes.
[1]A 28-amino-acid endogenous neuropeptide originally isolated from porcine intestine. VIP functions as a neurotransmitter, vasodilator, and immunomodulator with extensive distribution throughout the central nervous system, gastrointestinal tract, lungs, reproductive tract, and immune tissues.
VIP has potent anti-inflammatory and immunoregulatory effects, with clinical applications in sarcoidosis, pulmonary inflammation, and chronic inflammatory conditions. Aviptadil is a synthetic VIP analog investigated for COVID-19 ARDS.
At a glance
- Type
- 28-amino-acid endogenous neuropeptide, originally isolated from porcine intestine
- Receptors
- VPAC1 and VPAC2 G-protein coupled receptors on immune cells, neurons, and vascular endothelium
- Routes
- Subcutaneous, intranasal, inhaled (nebulized Aviptadil)
- Regulatory
- FDA fast-track ARDS designation for Aviptadil (COVID-19)
- Dose-limiting effect
- Facial flushing from vasodilation; start low and titrate
- Handling
- Refrigerate and protect from light
What the research supports
VIP's evidence base spans potent anti-inflammatory immunomodulation, FDA fast-track ARDS designation for Aviptadil, and emerging orthopedic applications.
Aviptadil ARDS Meta-Analysis
Aviptadil therapy showed improvements in oxygenation and inflammation in ARDS but no statistically significant survival benefit; mechanism supported, mortality effect modest.
[2]VPAC1/VPAC2 Receptor Mechanism
Binds VPAC1 and VPAC2 G-protein coupled receptors on immune cells, neurons, and vascular endothelium; modulates Th1/Th17 vs Treg balance toward immune tolerance.
[3]Cytokine Modulation
Reduces TNF-alpha, IL-1 beta, IL-6, IL-8. Increases IL-10, shifting the immune environment toward resolution and tolerance.
[3]Summary of key findings
Potent Anti-Inflammatory
Comprehensive cytokine modulation across both arms of immunity; not a marginal molecule. Reduces pro-inflammatory markers while elevating IL-10.
Sarcoidosis Flagship Indication
Deepest evidence base in sarcoidosis and granulomatous disease. Chronic inflammatory response syndromes represent the strongest clinical application.
Flushing is Dose-Limiting
Vasodilator effect drives facial flushing; start low at 25 to 50 mcg and titrate gradually to minimize adverse vasodilatory response.
Fragile Peptide
Storage and handling matter unusually for VIP. Counsel patients on refrigeration and protection from light to preserve peptide integrity.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Subcutaneous Protocol
- 50 to 200 mcg 1 to 3 times daily. Lower starting doses of 25 to 50 mcg reduce flushing. Titrate up over weeks.
- Intranasal (Functional Medicine)
- 50 to 200 mcg per spray; multiple daily doses common in CIRS protocols. Minimum 4 months recommended.
- Inhaled Aviptadil (ARDS)
- Clinical trial protocols use 100 to 200 mcg three times daily nebulized.
- Cycling
- 8 to 12 week courses typical; CIRS protocols often run 6 to 12 months with periodic reassessment.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| VIP 6 mg nasal | 100 to 500 mcg (1 to 5 sprays) | 1 to 5 sprays (10 units per spray) | Daily, AM empty stomach | Nasal route. Minimum 4 months, maintenance after. |
| VIP 6 mg SC | 100 mcg starter, titrating to 200 or 400 mcg per day | Daily, AM empty stomach | Subcutaneous route. Titrate up over weeks. 1 vial = 15 days at 400 mcg per day. |
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
VIP is one of the most clinically interesting anti-inflammatory peptides because of its potency, breadth of effect, and the FDA fast-track designation that Aviptadil received for COVID-19 ARDS. The strongest clinical applications are chronic inflammatory conditions where conventional therapy has failed: sarcoidosis, inflammatory bowel disease, and CIRS protocols.
Recent 2026 osteoarthritis work opens an interesting regenerative orthopedic application. Frame the ARDS application honestly: Aviptadil showed improvements in oxygenation and inflammation, but the 2025 meta-analysis did not demonstrate statistically significant survival benefit.
Flushing is the most common dose-limiting side effect; start low and titrate up gradually. Hypotension monitoring matters in patients on antihypertensives. Storage and handling are unusually important for VIP.
Sarcoidosis and CIRS
Deepest evidence base in chronic granulomatous and inflammatory response syndromes. Pairs with KPV for combined anti-inflammatory protocols.
Pulmonary Inflammation
Aviptadil ARDS work supports mechanistic case despite mortality null result. BPC-157 pairing for tissue repair.
Joint Inflammation
2026 chondrogenesis data opens regenerative orthopedic applications in osteoarthritis and cartilage repair.
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Tecza et al., 2026 VIP Advances Chondrogenesis in Osteoarthritis
- 2Udupa et al., 2025 Aviptadil ARDS Meta-Analysis
- 3VIP and Immune Regulation ReviewCitation under review
- 4Prasse et al., 2010 VIP in Sarcoidosis Pilot Study
Regulatory status, cautions and contraindications
Hypotension
Monitor in patients with low blood pressure or on antihypertensives. Vasodilatory effects require careful cardiovascular assessment.
Active Malignancy
Relative caution warranted. VIP receptors are expressed on some tumor types; individualized risk-benefit assessment required.
Severe Cardiovascular Disease
Caution due to vasodilatory effects. Thorough cardiovascular evaluation before initiating therapy is essential.
Pregnancy and Lactation
Insufficient safety data available. Avoid use during pregnancy and lactation until adequate evidence is established.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.